These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 7949832

  • 1. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience.
    Paulson RJ, Sauer MV, Lobo RA.
    J Assist Reprod Genet; 1994 Jan; 11(1):28-32. PubMed ID: 7949832
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report.
    Cassidenti DL, Sauer MV, Paulson RJ, Ditkoff EC, Rivier J, Yen SS, Lobo RA.
    Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1806-10. PubMed ID: 1750479
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
    Frydman R, Cornel C, de Ziegler D, Taieb J, Spitz IM, Bouchard P.
    Fertil Steril; 1991 Nov; 56(5):923-7. PubMed ID: 1936328
    [Abstract] [Full Text] [Related]

  • 11. Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase.
    Frydman R, Cornel C, de Ziegler D, Taieb J, Spitz IM, Bouchard P.
    Hum Reprod; 1992 Aug; 7(7):930-3. PubMed ID: 1430131
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The utility of a midcycle follicle-stimulating hormone boost in addition to human chorionic gonadotropin for timing of follicle aspiration in unstimulated in vitro fertilization cycles.
    Lindheim SR, Sauer MV, Francis MM, Macaso T, Lobo R, Paulson RJ.
    Gynecol Obstet Invest; 1997 Aug; 43(2):76-8. PubMed ID: 9067710
    [Abstract] [Full Text] [Related]

  • 14. Gonadotropin requirements of the developing follicle.
    Thompson KA, LaPolt PS, River J, Henderson G, Dahl KD, Meldrum DR.
    Fertil Steril; 1995 Feb; 63(2):273-6. PubMed ID: 7843430
    [Abstract] [Full Text] [Related]

  • 15. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlou SN.
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.